|  |
| --- |
| ICMJE DISCLOSURE FORM |
| **Date:** | 12/15/2021 |
| **Your Name:** | Michael Kaufman |
| **Manuscript Title:** | One year of child neurology telemedicine: a data-driven analysis of 14,820 encounters |
| **Manuscript Number (if known):** | Click or tap here to enter text. |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |

|  | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
| --- | --- | --- |
| **Time frame: Since the initial planning of the work** |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

 |
| **Time frame: past 36 months** |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| Pfizer, Miles for Migraine | Christina Szperka has received grant support |
| NIH NINDS | Christina Szperka has received grant support and was supported in part by this grant |
| Hartwell Foundation | Ingo Helbig was supported in part by this grant |
| National Institute for Neurological Disorders and Stroke | Ingo Helbig was supported in part by this grant |
| Center Without Walls on ion channel function in epilepsy | Ingo Helbig was supported in part by this grant |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development | Ingo Helbig was supported in part by this grant |
| National Center for Advancing Translational Sciences of the National Institutes of Health through the Institute for Translational Medicine and Therapeutics’ (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics | Ingo Helbig was supported in part by this grant |
| Wolfson Foundation | Research funding for Nicholas Abend |
| PCORI | Research funding for Nicholas Abend |
| UCB Pharma | Research funding for Nicholas Abend |
| Children’s Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative (ENGIN) | Ingo Helbig was supported in part by this intramural funding |

 |
| **3** | Royalties or licenses |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| Demos Publishing | Nicholas Abend receives royalties |
|  |  |
|  |  |

 |
| **4** | Consulting fees |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| Epilepsy Foundation | Nicholas Abend is a consultant |
| Allergan | Christina Szperka/her institution have consulted |
| Teva | Christina Szperka/her institution have consulted |
| Lundbeck | Christina Szperka/her institution have consulted |
| Impel | Christina Szperka/her institution have consulted |
| Eli Lilly | Christina Szperka/her institution have consulted |
| Upsher Smith | Christina Szperka/her institution have consulted |

 |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **6** | Payment for expert testimony |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **7** | Support for attending meetings and/or travel |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **8** | Patents planned, issued or pending |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| Biogen | Ingo Helbig serves on their Scientific Advisory Board |
|  |  |
|  |  |

 |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **11** | Stock or stock options |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **13** | Other financial or non-financial interests |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
|  |  |  |
| **Please place an “X” next to the following statement to indicate your agreement:** |
|[x]  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |